Last reviewed · How we verify
AD 237
AD 237 is a selective antagonist of the adenosine A2A receptor that blocks immunosuppressive signaling in the tumor microenvironment.
AD 237 is a selective antagonist of the adenosine A2A receptor that blocks immunosuppressive signaling in the tumor microenvironment. Used for Advanced solid tumors (Phase 2 development).
At a glance
| Generic name | AD 237 |
|---|---|
| Sponsor | Sosei |
| Drug class | Adenosine A2A receptor antagonist |
| Target | Adenosine A2A receptor (A2AR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Adenosine A2A receptor antagonism reduces the immunosuppressive effects of adenosine on T cells and natural killer cells, thereby enhancing anti-tumor immune responses. This mechanism is intended to work synergistically with checkpoint inhibitors or as a monotherapy to reinvigorate anti-tumor immunity in the tumor microenvironment.
Approved indications
- Advanced solid tumors (Phase 2 development)
Common side effects
- Headache
- Fatigue
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AD 237 CI brief — competitive landscape report
- AD 237 updates RSS · CI watch RSS
- Sosei portfolio CI